Joshua D Rosenblat
Overview
Explore the profile of Joshua D Rosenblat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
255
Citations
5210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Llach C, Le G, Badulescu S, Anmella G, Hasan H, Gimenez-Palomo A, et al.
Eur Neuropsychopharmacol
. 2025 Mar;
94:59-75.
PMID: 40057988
Extracellular vesicles (EVs) are small, membrane-bound particles that are naturally released by nearly all cell types in the body. They serve as molecular biosignatures, reflecting the state of their cells...
2.
Myran D, Xiao J, Fabiano N, Pugliese M, Kaster T, Rosenblat J, et al.
CMAJ
. 2025 Mar;
197(8):E204-E213.
PMID: 40032291
Background: Although clinical trials involving psychedelic-assisted psychotherapy have not observed short-term increases in the risk of death, limited data exist on mortality associated with hallucinogen use outside of controlled trial...
3.
McIntyre R, Rasgon N, Goldberg J, Goldberg J, Wong S, Le G, et al.
CNS Spectr
. 2025 Feb;
:1-25.
PMID: 39964126
No abstract available.
4.
Valentino K, Teopiz K, Cheung W, Wong S, Le G, Rosenblat J, et al.
J Psychiatr Res
. 2025 Feb;
183:112-126.
PMID: 39956093
Reports submitted to the FDA and EMA suggest that Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) may be associated with an elevated risk of suicidality. To ascertain this association across available...
5.
Au H, Zheng Y, Le G, Wong S, Teopiz K, Kwan A, et al.
Acta Neuropsychiatr
. 2025 Feb;
:1-25.
PMID: 39950609
Objective: Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) administration has been associated with neuroproliferative effects and modulatory effects in neuronal pathways. Herein, we conducted a comprehensive synthesis...
6.
Kwan A, Lakhani M, Teopiz K, Wong S, Le G, Ho R, et al.
J Affect Disord
. 2025 Jan;
374:390-396.
PMID: 39818335
Background And Objective: To determine whether there is disproportionate reporting of hepatobiliary disorders in the United States (US) FDA Adverse Event Reporting System (FAERS) for individuals prescribed ketamine or esketamine....
7.
Mansur R, Di Vincenzo J, Badulescu S, Gill H, Tabassum A, Lopez C, et al.
CNS Spectr
. 2025 Jan;
29(6):536-541.
PMID: 39801083
Incretin-based treatments, such as glucagon-like peptide-1 receptor (GLP-1R) agonists (eg liraglutide and semaglutide), have rapidly transformed obesity treatment. The well-documented weight loss effect from these agents is considered to be...
8.
Tamura J, Harangi D, Rodrigues N, Mansur R, Subramaniapillai M, Johnson D, et al.
CNS Spectr
. 2025 Jan;
29(6):697-704.
PMID: 39789718
Background: Improving functioning in adults with major depressive disorder (MDD) and bipolar disorder (BD) is a priority therapeutic objective. Methods: This retrospective post hoc secondary analysis evaluated 108 patients with...
9.
Le G, Wong S, Kwan A, Rosenblat J, Mansur R, Teopiz K, et al.
CNS Spectr
. 2025 Jan;
29(6):682-696.
PMID: 39757482
Background: Antidepressants are commonly prescribed for mood disorders. Epidemiological studies suggest antidepressant use may be associated with cataracts and glaucoma. We aim to investigate the association between antidepressants and cataracts...
10.
McIntyre R, Kwan A, Mansur R, Oliveira-Maia A, Teopiz K, Maletic V, et al.
Am J Psychiatry
. 2025 Jan;
182(1):21-32.
PMID: 39741444
During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain...